SBIR Phase I: Improved in Vivo Delivery of SiRNA

SBIR 第一阶段：改善 siRNA 的体内递送

• 批准号: 0738167
• 负责人: Lance Ford
• 金额: --
• 依托单位: Bioo Scientific Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0738167&HistoricalAwards=false
• 关键词: SBIR; Phase; Improved; Vivo; Delivery

PARS SummaryThis Small Business Innovation Research (SBIR) Phase I research project aims to develop an improved method for the delivery of small inhibitory ribonucleic acids (siRNA) into cells. The proposed methodology will utilize chemically induced immuno-conjugates or direct linking of siRNAs to antibodies as the mechanism for improving siRNA delivery into the cells. Use of siRNA to silence genes of interest has become a very important mechanism to regulate gene expression both in experimental settings as well as in diseases. One of the current limitations to using siRNA therapy in vivo is the low uptake by the cells. Methods that improve siRNA uptake by target cells would therefore be of great benefit to the scientific and medical communities. The use of the cellular uptake mechanisms for the delivery of these potent regulatory molecules into cells further opens the possibility of using specific gene silencing molecules as therapeutic modalities in vivo.

PARS 摘要这个小企业创新研究 (SBIR) 第一阶段研究项目旨在开发一种改进的方法，用于将小抑制性核糖核酸 (siRNA) 递送到细胞中。 所提出的方法将利用化学诱导的免疫缀合物或 siRNA 与抗体的直接连接作为改善 siRNA 递送到细胞中的机制。 使用 siRNA 沉默感兴趣的基因已成为在实验环境和疾病中调节基因表达的非常重要的机制。 目前在体内使用 siRNA 疗法的限制之一是细胞的低摄取。 因此，提高靶细胞对 siRNA 摄取的方法将对科学界和医学界大有裨益。 使用细胞摄取机制将这些有效的调节分子递送到细胞中进一步开启了使用特定基因沉默分子作为体内治疗方式的可能性。